Fulcrum Therapeutics Inc

Simply Wall St has raised its Fair Value estimate for Fulcrum Therapeutics to US$5.83 per share from US$5.43, reflecting updated analyst assumptions after the company discontinued its sickle cell disease drug pociredir. The revision incorporates a higher projected revenue growth rate of 216.56%, an improved net profit margin expectation of 21.87%, and a lower future price-to-earnings multiple of 96.08 times, while the discount rate remained at 7.11%. The adjustment comes as multiple Wall Street firms, including Piper Sandler, BofA, Stifel, Truist, H.C. Wainwright, and Leerink, cut ratings and set price targets in a US$3 to US$4 range, with Goldman Sachs suspending its rating and JPMorgan moving to Underweight. Analysts now focus on Fulcrum's cash-rich balance sheet, with Truist estimating cash at about US$4 per share, and on the ongoing strategic review rather than late-stage pipeline potential.

Fulcrum Therapeutics' modeled fair value has been cut by roughly 71%, from about US$19.00 to approximately US$5.43, following the discontinuation of pociredir and a shift in analyst focus to the company's cash position and strategic alternatives. Several firms, including JPMorgan, Piper Sandler, Stifel, Truist, Leerink, and H.C. Wainwright, moved to more cautious ratings, with price targets reset to a range of about US$3 to US$4, down from prior targets that were several times higher. Truist estimates cash value at about US$4 per share, which some investors may view as a backstop while the company reviews options. Goldman Sachs suspended its rating entirely after removing pociredir from pipeline models, indicating insufficient basis to frame upside or downside scenarios. The fair value revision also reflects adjustments to modeled revenue growth, net profit margin, future P/E, and discount rate.